HOB BIOTECH(SH:688656) Xin Lang Cai Jing·2025-11-24 06:04Group 1 - The core point of the article highlights the recent performance of Jiangsu Haobo Bio-Pharmaceutical Co., Ltd., which saw a 5.1% increase in stock price, reaching 183.80 yuan per share, with a trading volume of 146 million yuan and a turnover rate of 1.30%, resulting in a total market capitalization of 11.668 billion yuan [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with its main revenue sources being reagent sales (89.46%), other sales (5.86%), instrument sales (3.84%), and rental sales (0.85%) [1] Group 2 - From the perspective of fund holdings, only one fund under Industrial Bank has a significant position in Haobo Bio, specifically the Industrial Medical Care A fund, which held 96,900 shares in the third quarter, accounting for 3.8% of the fund's net value, making it the tenth largest holding [2] - The Industrial Medical Care A fund, established on March 8, 2021, has a current size of 261 million yuan, with a year-to-date return of 19.11%, ranking 3578 out of 8209 in its category, and a one-year return of 11.73%, ranking 4678 out of 8129 [2] - The fund manager, Chen Xu, has been in position for 4 years and 263 days, with the total asset size of the fund being 404 million yuan, and the best and worst returns during his tenure being -22.64% and -24.44%, respectively [2]